Does treatment with besudil affect white blood cell counts?

Belumosudil (belumosudil) is a drug used to treat chronic graft-versus-host disease (cGVHD). It is an oral selective Rhokinase 2 (ROCK2) inhibitor. By inhibiting ROCK2, it regulates the immune response, reduces excessive immune response, and relieves the symptoms of cGVHD patients. Although besudil has shown clinically significant therapeutic effects, its use may affect patients' hematological parameters, including white blood cell counts.

In clinical studies, besudil has been shown to cause certain hematological changes, with white blood cell counts being one of the most commonly affected. Specifically, some patients may experience leukopenia (i.e., a decrease in white blood cell count) during treatment with besudil. A decrease in white blood cells may increase the risk of infection, especially if the immune system is suppressed. Although this side effect is usually mild to moderate, in some patients the white blood cell count may be significantly reduced.

During the course of treatment, doctors usually regularly check the patient's hematological indicators, especially the white blood cell count, in order to detect abnormal changes in time. If leukopenia occurs, the doctor may adjust the dose of besudil according to the patient's specific situation, or take other supportive treatment measures, such as using growth factors to stimulate the production of white blood cells, or taking antibiotics to prevent infection.

For mild decreases in white blood cell count, patients may not need to discontinue medication but may use medication adjustments or supportive care to restore white blood cell levels. However, in cases of severely low white blood cell counts, doctors may consider suspending treatment until blood levels return to a safe range. When patients are treated with Besudil, they should communicate closely with their doctors, report any symptoms of infection, such as fever, cough, sore throat, etc., and follow the doctor's instructions for treatment and monitoring.

Reference materials:https://www.rezuomib.com/